Asivatrep

DB12428InvestigationalSmall molecule

PAC-14028 has been used in trials studying the treatment of Skin Pruritus, Papulopustular Rosacea, and Erythematotelangiectatic Rosacea.

Mechanism: Pharmacologically active on Transient receptor potential cation channel subfamily V member 1
Curator reviewed
Formula / weight: C₂₁H₂₂F₅N₃O₃S · 491.48 g/mol (avg)
Code names: PAC-14028

Resolves to

Compound

Structure

InChIKeyUKGJZDSUJSPAJL-YPUOHESYSA-NSMILESCCCC1=C(\C=C\C(=O)N[C@H](C)C2=CC(F)=C(NS(C)(=O)=O)C(F)=C2)C=CC(=N1)C(F)(F)F

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Asivatrep, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.